Immune checkpoint inhibitor‐induced vitiligo in advanced melanoma could be related to increased levels of CCL19
Taku Fujimura(Université Paris Cité), Setsuya Aiba(Tohoku University), Atsushi Otsuka(Kyoto University), Shigeto Matsushita(National Hospital Organization), Kenji Yoshino(Tokyo Metropolitan Komagome Hospital), Yasuhiro Fujisawa(University of Tsukuba), Takeru Funakoshi(Keio University), C. Lyu(Chinese Academy of Medical Sciences & Peking Union Medical College), Yumi Kambayashi(Tohoku University), Yuki Yamamoto(National Center For Child Health and Development), Hiroo Hata(Hokkaido University), Kayo Tanita(Tohoku University), Akira Hashimoto(Tohoku University), Hiroshi Uchi(Kyushu University), Y. Sato(Tohoku University), Satoshi Fukushima(Niigata Cancer Center Hospital)
Cited by 14
Related Papers
Dermatofibrosarcoma protuberans is a unique fibrohistiocytic tumour expressing CD34
|British Journal of Dermatology|1992|235
Notch signaling: Its role in epidermal homeostasis and in the pathogenesis of skin diseases
|Journal of Dermatological Science|2007|163
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
|Oncotarget|2016|160
p38 Mitogen-activated Protein Kinase and Extracellular Signal-regulated Kinases Play Distinct Roles in the Activation of Dendritic Cells by Two Representative Haptens, NiCl2 and 2,4-dinitrochlorobenzene
|Journal of Investigative Dermatology|2003|157
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients
|Annals of Oncology|2020|140